Clonidine sustained release - Tris Pharma

Drug Profile

Clonidine sustained release - Tris Pharma

Alternative Names: Nexiclon XR

Latest Information Update: 29 Nov 2012

Price : $50

At a glance

  • Originator Tris Pharma
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 28 Nov 2012 NextWave Pharmaceuticals has been acquired by Pfizer
  • 07 Jan 2011 Product launched for Hypertension (PO, tablet and suspension formulations)
  • 07 Dec 2009 Registered for Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top